The Authors Reply We would like to thank Dr. Nagashima and colleagues for their interest in our recent article (1). We agree that care must be taken when assessing the causality of uncommon drug-induced adverse reactions, which was mentioned as a potential limitation in our study (1). However, although Garratty stated that typical drug-induced autoimmune hemolytic anemia (AIHA) occurs soon after the administration of the drug (2), delayed-onset drug-induced AIHA cases that occur 24-60 months after cladribine administration have been reported (3); therefore, we cannot exclude the possibility of AIHA induced by adalimumab solely because of an unusually long latency period. A greater accumulation of cases is necessary in order to obtain a definitive answer regarding this issue.
